GSK plc presented data on the discovery of a selective and potent lead series for G protein-coupled receptor kinase 2 (GRK2) inhibition for the potential treatment of heart failure. Heart failure remains a leading cause of morbidity and mortality worldwide.
Southern Marine Science and Engineering Guangdong Laboratory and Guangdong Medical University have disclosed peptides acting as angiotensin-converting enzyme (ACE) inhibitors reported to be useful for the treatment of hypertension.
Rhizen Pharmaceuticals and Incozen Therapeutics have synthesized new cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, Alzheimer's disease, pulmonary fibrosis, inflammatory disorders, psoriasis and rheumatoid arthritis, among other disorders.
Using a knock-in mouse model of Brugada syndrome (BrS) with an SCN5A mutation identified in multiple BrS families (Scn5aG1746R/+), a team of scientists from various research institutions evaluated the effects of upregulation of MOG1 (ran guanine nucleotide release factor, RanGNRF) via adeno-associated virus serotype 9 (AAV9) vector delivery on BrS features.
Researchers from Cantargia and Johns Hopkins University School of Medicine presented data from a preclinical study evaluating an IL-1 receptor accessory protein (IL-1RAP)-blocking antibody, CAN-10, in a model of acute coxsackievirus B3 (CVB3) myocarditis.
RSS
